Vizsgálati helyszín
The Third People's Hospital of Chengdu
Chengdu, Sichuan 610031, KínaMég nincs intézményhez kötve
- 19futó vizsgálat
- 2lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 21 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis8 vizsgálat
- 2. fázis4 vizsgálat
- 1. fázis1 vizsgálat
- Állapot
- Toboroz9 vizsgálat
- Fut, nem toboroz5 vizsgálat
- Még nem toboroz5 vizsgálat
- Lezárult2 vizsgálat
- Fő szponzor
- The Third People's Hospital of Chengdu5 vizsgálat
- Janssen Research & Development, LLC4 vizsgálat
- West China Hospital3 vizsgálat
- Guangdong Association of Clinical Trials2 vizsgálat
- Beijing Anzhen Hospital1 vizsgálat
- és még 6
Futó vizsgálatok
Toboroz
Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer
NCT07855965· 2. fázis· West China Hospital· Forrás
Contact: Yi Yang
Toboroz
DEC003M in Prostate Cancer
NCT07657806· 1. fázis· Hangzhou DAC Biotechnology Co., Ltd.· Forrás
Contact: Hui Zhuo, MD (Doctor of Medicine)
Toboroz
Helium-free Magnetocardiography Guided Therapy for Stable Coronary Artery Disease - A Randomized Controlled Trial
NCT07341932· Beijing Anzhen Hospital· Forrás
Contact: Zhen Zhang
Toboroz
A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
NCT07444437· 2. fázis· Suzhou BlueHorse Therapeutics Co., Ltd.· Forrás
Contact: Yi Yang
Toboroz
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
NCT07168161· 3. fázis· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Forrás
Contact: Guisen Li
Toboroz
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
NCT07120698· 2. fázis· Guangdong Association of Clinical Trials· Forrás
Contact: Yi Y Yang
Toboroz
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
FIH Study of PFLotus in Persistent Atrial Fibrillation
NCT07301190· The Third People's Hospital of Chengdu· Forrás
Contact: Shiqiang Xiong, Doctor of Medicine
Toboroz
Evaluating the Safety and Effectiveness of 5G Cloud Follow-up for Cardiovascular Implantable Electronic Devices
NCT06652750· The Third People's Hospital of Chengdu· Forrás
Contact: Yan Luo, master of medicine
Fut, nem toboroz
Using a Novel Balloon-shaped Large-Focal Pulsed Field Ablation Catheter in Persistent Atrial Fibrillation
NCT07294742· The Third People's Hospital of Chengdu· Forrás
Még nem toboroz
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
NCT06709274· Guangdong Association of Clinical Trials· Forrás
Contact: Yi Yang, MD
Toboroz
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
NCT06128252· Tang-Du Hospital· Forrás
Contact: Yingxin Wu, Master
Fut, nem toboroz
FIH of PFBalloon for PVI
NCT07320976· The Third People's Hospital of Chengdu· Forrás
Toboroz
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)
NCT06242418· 2. fázis· West China Hospital· Forrás
Contact: Zhang Yuanchuan
Fut, nem toboroz
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer
NCT04922853· 3. fázis· West China Hospital· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek